Quantum BioPharma Appoints Multiple Sclerosis Expert Dr. Jack Antel as Clinical Advisor for Lucid-MS Development
TL;DR
Quantum BioPharma gains a competitive edge by appointing renowned MS expert Dr. Jack Antel to guide Lucid-MS into Phase 2 trials, accelerating development of their patented demyelination inhibitor.
Dr. Antel will design efficacy trials for Lucid-MS, Quantum BioPharma's investigational drug that inhibits demyelination in multiple sclerosis, as it advances into Phase 2 studies.
This appointment advances development of Lucid-MS, potentially improving treatment for multiple sclerosis patients by addressing the underlying mechanism of myelin degradation.
Quantum BioPharma adds Dr. Jack Antel, a Dystel Award-winning neurologist with 450+ publications, to their clinical advisory team alongside Dr. Peter Stys for MS drug development.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has appointed Dr. Jack Antel, a world-renowned multiple sclerosis expert and Professor of Neurology at McGill University, as clinical advisor to support the development of Lucid-21-302, the company's patented investigational drug designed to inhibit demyelination in MS. This strategic appointment represents a significant advancement in Quantum BioPharma's multiple sclerosis program as the company prepares to advance Lucid-MS into Phase 2 clinical studies.
Dr. Antel brings exceptional credentials to the role, having received the National Multiple Sclerosis Society and American Academy of Neurology's Dystel Award and authored over 450 published articles in the field. His primary responsibility will involve guiding the design of efficacy trials for Lucid-MS, which has shown promise in preclinical models by demonstrating the ability to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Dr. Antel joins Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, who continues to serve as clinical advisor, creating a formidable team of neurological experts.
The appointment of such a distinguished MS specialist underscores the potential significance of Lucid-MS in treating multiple sclerosis, a chronic autoimmune disease that affects approximately 2.8 million people worldwide. Current MS treatments primarily focus on managing symptoms and reducing relapse rates, but few address the fundamental process of demyelination that causes progressive disability. Lucid-MS represents a novel approach as a patented new chemical entity specifically designed to target myelin degradation, potentially offering a more fundamental treatment strategy for MS patients.
Quantum BioPharma's focus on neurodegenerative disorders extends beyond multiple sclerosis, with the company dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company maintains its research and development focus on Lucid-MS as its lead compound. Additional corporate activities include the spin-out of its unbuzzd™ product to Unbuzzd Wellness Inc., with Quantum BioPharma retaining 20.11% ownership and receiving royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
The company maintains access to investor information through its newsroom at https://ibn.fm/QNTM, providing ongoing updates about its development programs and corporate activities. The advancement of Lucid-MS into Phase 2 studies under the guidance of leading neurological experts like Dr. Antel represents a critical milestone in the drug development pathway, potentially bringing new hope to MS patients seeking treatments that address the core pathology of their condition rather than merely managing symptoms.
Curated from InvestorBrandNetwork (IBN)
